Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of ATB-346 (Otenaproxesul) in Osteoarthritis of the Knee
NCT03978208Phase 2Completed
- Sponsor
- Antibe Therapeutics Inc.
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of otenaproxesul in knee osteoarthritis (OA) (4 arms), sponsored by Antibe Therapeutics Inc. Primary endpoint: WOMAC Pain Subscale Score Change from Baseline at 14 days. Started Mar 2019; status: completed.
02
Drugs
otenaproxesul
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03978208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978208.